Roben Gieling Senior Lecturer

Dr Roben Gieling

Assistant Professor

Department: Applied Sciences

Roben Gieling Academic Staff, Faculty of Life and Health Sciences, 51��

Roben began his scientific career in Biomedical Science with the University of Utrecht (Master’s programme in Medical Biology), which included two placements in the University Medical Centre Utrecht, and graduated in 1997.

His time as scientific staff with the RWTH Aachen University (Neurology Department 1997-98) was followed by a postgraduate study at the University of Amsterdam (Department of Anatomy and Embryology) on “Changes in Blood Flow that Affect Hepatic Gene Expression”, where he received a PhD in Medicine in 2005.

Roben undertook postdoctoral research in world leading research groups at USC Los Angeles (Prof Han), Newcastle University (Prof Mann) and the University of Manchester (Prof Williams) contributing to 19 highly regarded papers, in Oncology, Imaging and Hepatology fields. In his role as guest lecturer and tutor he contributed to the Pharmacy and Medicine undergraduate education in the University of Manchester. There he supervised 3 PhD students

He joined the Department of Applied Sciences in July 2018 as Senior Lecturer in Histopathology where he will contribute to the Biomedical Science programmes, and use his expertise to establish his own research group.

Campus Address

NB148, Northumberland Building
51��
Newcastle upon Tyne
NE21HL

Email Roben

Key Publications

Next generation organoid engineering to replace animals in cancer drug testing, Hockney, S., Parker, J., Turner, J., Todd, X., Todryk, S., Ger Gieling, R., Hilgen, G., Camargo Madeira Simoes, D., Pal, D. 1 Jul 2023, In: Biochemical Pharmacology
A Novel Mechanism of Ataxia Telangiectasia Mutated Mediated Regulation of Chromatin Remodeling in Hypoxic Conditions, Likhatcheva, M., Gieling, R., Brown, J., Demonacos, C., Williams, K. 21 Sep 2021, In: Frontiers in Cell and Developmental Biology
Preclinical Evaluation of Ureidosulfamate Carbonic Anhydrase IX/XII Inhibitors in the Treatment of Cancers, Williams, K., Gieling, R. 2 Dec 2019, In: International Journal of Molecular Sciences
A new method for the high-precision assessment of tumor changes in response to treatment, Tar, P., Thacker, N., Babur, M., Watson, Y., Cheung, S., Little, R., Gieling, R., Williams, K., O'Connor, J. 14 Mar 2018, In: Bioinformatics
Novel carbonic anhydrase IX-targeted therapy enhances the anti-tumour effects of cisplatin in small cell lung cancer, Bryant, J., Meredith, S., Gieling, R., Allen, T., Walker, L., Telfer, B., Supuran, C., Williams, K., White, A. 1 Jan 2018, In: International Journal of Cancer
The Sulfamate Small Molecule CAIX Inhibitor S4 Modulates Doxorubicin Efficacy, van Kuijk, S., Gieling, R., Niemans, R., Lieuwes, N., Biemans, R., Telfer, B., Haenen, G., Yaromina, A., Lambin, P., Dubois, L., Williams, K. 11 Aug 2016, In: PLoS One
Dissemination via the lymphatic or angiogenic route impacts the pathology, microenvironment and hypoxia-related drug response of lung metastases, Gieling, R., Fitzmaurice, R., Telfer, B., Babur, M., Williams, K. Aug 2015, In: Clinical and Experimental Metastasis
Erratum: NFκB1 is a suppressor of neutrophil-driven hepatocellular carcinoma (Nature Communications (2015) 6 (6818) DOI: 10.1038/ncomms7818), Wilson, C., Jurk, D., Fullard, N., Banks, P., Page, A., Luli, S., Elsharkawy, A., Gieling, R., Chakraborty, J., Fox, C., Richardson, C., Callaghan, K., Blair, G., Fox, N., Lagnado, A., Passos, J., Moore, A., Smith, G., Tiniakos, D., Mann, J., Oakley, F., Mann, D. 21 Sep 2015, In: Nature Communications
NFκB1 is a suppressor of neutrophil-driven hepatocellular carcinoma, Wilson, C., Jurk, D., Fullard, N., Banks, P., Page, A., Luli, S., Elsharkawy, A., Gieling, R., Chakraborty, J., Fox, C., Richardson, C., Callaghan, K., Blair, G., Fox, N., Lagnado, A., Passos, J., Moore, A., Smith, G., Tiniakos, D., Mann, J., Oakley, F., Mann, D. 16 Apr 2015, In: Nature Communications
Targeting tumour hypoxia to prevent cancer metastasis: From biology, biosensing and technology to drug development: the METOXIA consortium, Pettersen, E., Ebbesen, P., Gieling, R., Williams, K., Dubois, L., Lambin, P., Ward, C., Meehan, J., Kunkler, I., Langdon, S., Ree, A., Flatmark, K., Lyng, H., Calzada, M., Peso, L., Landazuri, M., Görlach, A., Flamm, H., Kieninger, J., Urban, G., Weltin, A., Singleton, D., Haider, S., Buffa, F., Harris, A., Scozzafava, A., Supuran, C., Moser, I., Jobst, G., Busk, M., Toustrup, K., Overgaard, J., Alsner, J., Pouyssegur, J., Chiche, J., Mazure, N., Marchiq, I., Parks, S., Ahmed, A., Ashcroft, M., Pastorekova, S., Cao, Y., Rouschop, K., Wouters, B., Koritzinsky, M., Mujcic, H., Cojocari, D. 3 Sep 2015, In: Journal of Enzyme Inhibition and Medicinal Chemistry

+

Northumbria Open Days

Open Days are a great way for you to get a feel of the University, the city of Newcastle upon Tyne and the course(s) you are interested in.

+

Research at Northumbria

Research is the life blood of a University and at 51�� we pride ourselves on research that makes a difference; research that has application and affects people's lives.